Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22663486 | 0.83 | MAPT (0.42) | MAPTALDH1A1TSHRALOX15HSD17B10 | |
| SCHEMBL21226943 | 0.83 | MAPT (0.42) | MAPTALDH1A1TSHRALOX15HSD17B10 | |
| SCHEMBL19121975 | 0.83 | ALDH1A1 (0.42) | MAPTALDH1A1TSHRALOX15HSD17B10 | |
| SCHEMBL20034026 | 0.82 | ALDH1A1 (0.46) | MAPTALDH1A1TSHRALOX15HSD17B10 | |
| SCHEMBL12666676 | 0.81 | ALDH1A1 (0.43) | MAPTALDH1A1TSHRALOX15HSD17B10 | |
| SCHEMBL26223336 | 0.80 | ALDH1A1 (0.43) | MAPTALDH1A1TSHRALOX15HSD17B10 | |
| SCHEMBL10471439 | 0.77 | MAPT (0.41) | MAPTALDH1A1ALOX15HSD17B10MEN1 | |
| SCHEMBL13528295 | 0.77 | ALDH1A1 (0.40) | ALDH1A1TSHRALOX15HSD17B10TERT | |
| SCHEMBL13216543 | 0.77 | NR1H4 (0.48) | MAPTALDH1A1TSHRALOX15HSD17B10 | |
| SCHEMBL26245512 | 0.76 | ALDH1A1 (0.41) | MAPTALDH1A1TSHRALOX15APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20180224577-A1 | SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME | NATIONAL INSTITUTE OF INFORMATION AND COMMUNICATIONS TECHNOLOGY (JP) | 2018-08-09 | — | — | US | disclosed |
| US-9977150-B2 | Second-order nonlinear optical compound and nonlinear optical element comprising the same | NATIONAL INSTITUTE OF INFORMATION AND COMMUNICATIONS TECHNOLOGY (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9488755-B2 | Second-order nonlinear optical compound and nonlinear optical element comprising the same | NATIONAL INSTITUTE OF INFORMATION AND COMMUNICATIONS TECHNOLOGY (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160318889-A1 | SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME | NAT INST INF & COMM TECH (JP) | 2016-11-03 | — | — | US | disclosed |
| US-20150048284-A1 | SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME | NAT INST INF & COMM TECH (JP) | 2015-02-19 | — | — | US | disclosed |
| US-8846955-B2 | Second-order nonlinear optical compound and nonlinear optical element comprising the same | NATIONAL INSTITUTE OF INFORMATION AND COMMUNICATIONS TECHNOLOGY (JP) | 2014-09-30 | — | — | US | disclosed |
| US-20120172599-A1 | SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME | SUMITOMO ELECTRIC INDUSTRIES, LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-8119812-B2 | Thiazolidinone derivative | SBI BIOTECH CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-8119812-B2 | Thiazolidinone derivative | SBI BIOTECH CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | SBI BIOTECH CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | SBI BIOTECH CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318889-A1 | SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME | OGFOD1, OCIAD2, OCIAD1 | MAPT 2069/4885ALDH1A1 1660/4885TSHR 3930/4885 |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | CDC7, CDK17, CDCA2 | MAPT 3657/4885ALDH1A1 2165/4885TSHR 2727/4885 |
| US-20150048284-A1 | SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME | OGFOD1, OCIAD2, OCIAD1 | MAPT 2069/4885ALDH1A1 1660/4885TSHR 3930/4885 |
| US-20180224577-A1 | SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME | OGFOD1, OCIAD2, OCIAD1 | MAPT 2069/4885ALDH1A1 1660/4885TSHR 3930/4885 |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TRPC5, TRPC1, GOT1 | MAPT 24/4885ALDH1A1 2155/4885TSHR 2680/4885 |
| US-20120172599-A1 | SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME | OGFOD1, OCIAD2, OCIAD1 | MAPT 2069/4885ALDH1A1 1660/4885TSHR 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.